FDA regulators this month unveiled a series of warning letters issued to Dr. Pattanam Srinivasan, saying that the doctor authorized, sponsored and oversaw unapproved human experiments at the Indiana-based Advanced Interventional Pain Center.
Patient Safety
Boxer: Curbing medical errors will save thousands of lives, billions of dollars per year
Preventable hospital injuries claim as many as 440,000 patients’ lives each year, representing a woefully under-met area of clinical need, according to a new report released by Sen. Barbara Boxer (D-Calif.).
Sen. Boxer called on hospitals and clinics to devise and share ways to minimize common hospital injuries, such as infections and adverse drug events, in order to prevent needless deaths.
Stryker closes $120M Patient Safety Tech buy
Stryker (NYSE:SYK) closed its $2.22-per-share buyout of California safety-sponge maker Patient Safety Technologies in a deal valued at about $120 million.
Unveiled emails raise eyebrows about J&J’s ties to consulting docs
The growing patient injury lawsuits against Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon’s pelvic mesh products have raised some new questions about the relationships between industry and healthcare providers.
Valor Medical and execs plead guilty to concealing device toxicity from FDA
California biotech company Valor Medical, 4 executives and a consultant admitted to the Dept. of Justice that they concealed information about their Neucrylate diagnostic assay, hiding toxicity reports that were required as the product was undergoing FDA premarket review.
Health quality president Cassel reluctantly ditches board seats amid conflict scandal
National Quality Forum president & CEO Dr. Christine Cassel voluntarily resigned her seat on the boards of a couple of high-profile healthcare industry groups as questions continue to swirl about potential conflicts of interest among the Forum’s leaders.
Patient safety and medical professionalism: How far do the conflicts go?
Payments to CEO raise new conflicts at top health quality group
by Marshall Allen, ProPublica
NEJM backs ChloraPrep study in patient safety scandal
A review by the New England Journal of Medicine of data from a 2010 study it published on CareFusion‘s (NYSE:CFN) ChloraPrep antiseptic found that both the company and the doctor in charge of the study acted appropriately, the journal told MassDevice.com today.
Senator cites ‘serious concerns,’ demands National Quality Forum records
by Marshall Allen, ProPublica
An influential senator is demanding copies of contracts and conflict-of-interest policies from the National Quality Forum after allegations that kickbacks were paid to influence its patient safety guidelines.